ArticleClinical, cosmetic and investigational dermatology2026
Successful Treatment of Localized Scleroderma in Intertriginous Areas with Tofacitinib: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized scleroderma (LS) is a chronic skin disorder marked by excessive collagen deposition. We report a 61-year-old woman with LS predominantly affecting intertriginous areas, refractory to conventional therapies, who was treated with the Janus kinase 1/3 (JAK1/3) inhibitor tofacitinib at 5 mg twice daily, later reduced to 5 mg once daily for maintenance. Within two months, she experienced rapid relief of pruritus and marked softening of skin induration, with Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) scores improving from 5 to 1 on the LoSAI and from 3 to 2 on the LoSDI. No adverse effects were observed, and the patient reported high satisfaction. This case suggests that tofacitinib may represent a potential therapeutic option for patients with refractory LS, warranting further studies to clarify its long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.